VolitionRX (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Wednesday. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14), Fidelity Earnings reports.
NYSEAMERICAN VNRX opened at $2.70 on Friday. VolitionRX has a 12-month low of $1.44 and a 12-month high of $4.00.
In other VolitionRX news, Director Guy Archibald Innes acquired 50,000 shares of the business’s stock in a transaction on Thursday, August 16th. The stock was purchased at an average price of $2.00 per share, with a total value of $100,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Read More: Balance Sheet
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.